The Notice of Allowance for a patent covering setanaxib in cancer treatment is a significant positive development for Calliditas. It not only strengthens the company's intellectual property portfolio but also enhances its competitive position in the oncology market. The patent protection until 2038 provides a long runway for potential commercialization and revenue generation from setanaxib, especially in the niche of treating solid tumors resistant to PD-1 inhibitor immunotherapy.